Literature DB >> 12238569

Antimicrobial susceptibility of Bacillus anthracis in an endemic area.

Mustafa Z Bakici1, Nazif Elaldi, Mehmet Bakir, Ilyas Dökmetaş, Memnune Erandaç, Mustafa Turan.   

Abstract

We aimed to test the antimicrobial susceptibility of 28 Bacillus anthracis strains isolated from cutaneous anthrax cases to various antimicrobial agents using the Sceptor automatic system in an anthrax endemic area. All strains tested were susceptible to penicillin (MIC < or = 0.03 microg/ml). Piperacillin-tazobactam and carbapenems showed good activity towards all strains. Trimethoprim-sulfamethoxazole and cefepime had no activity. Strains were also tested with other antimicrobials.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12238569     DOI： 10.1080/00365540210147679

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN： 0036-5548


  4 in total

1.  Beta-lactamase gene expression in a penicillin-resistant Bacillus anthracis strain.

Authors:  Yahua Chen; Fred C Tenover; Theresa M Koehler
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

2.  Functional cloning of Bacillus anthracis dihydrofolate reductase and confirmation of natural resistance to trimethoprim.

Authors:  Esther W Barrow; Philip C Bourne; William W Barrow
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

3.  Evaluation of the metS and murB loci for antibiotic discovery using targeted antisense RNA expression analysis in Bacillus anthracis.

Authors:  G C Kedar; Vickie Brown-Driver; Daniel R Reyes; Mark T Hilgers; Mark A Stidham; Karen Joy Shaw; John Finn; Robert J Haselbeck
Journal:  Antimicrob Agents Chemother       Date:  2007-03-05       Impact factor: 5.191

4.  In vitro efficacy of new antifolates against trimethoprim-resistant Bacillus anthracis.

Authors:  Esther W Barrow; Jürg Dreier; Stefan Reinelt; Philip C Bourne; William W Barrow
Journal:  Antimicrob Agents Chemother       Date:  2007-09-17       Impact factor: 5.191
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.